Unigene Continues Solid Execution of Focused Turnaround Strategy and Monetizes Non-Core Asset with the Termination of China Joint Venture -Unigene to receive approximately $1MM …
Unigene Announces Manufacturing and Clinical Supply Agreement with Cara Therapeutics for Phase 1 Study of Novel Kappa Receptor Agonist Unigene's proprietary oral peptide delivery technology …
Unigene Announces Presentations on Proprietary Recombinant Production and Oral Peptide Drug Delivery Technology at Upcoming 2011 TIDES Summit Unigene Laboratories, Inc. (OTCBB: …